๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for ER+/HER2- Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site๐Ÿ“ Lebanon Dartmouth-Hitchcock Medical Center ยท Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Paderborn๐Ÿ“ Ravensburg iOMEDICO AG ยท Tests: Elacestrant, Standard of care (Investigator Choice) A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites๐Ÿ“ Miami๐Ÿ“ Boston๐Ÿ“ Durham Nancy Lin, MD ยท Tests: Datopotamab Deruxtecan A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites๐Ÿ“ Angers๐Ÿ“ Annecy๐Ÿ“ Avignon Royal Marsden NHS Foundation Trust ยท Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients NCT06195709Phase 321 sites๐Ÿ“ Bayonne๐Ÿ“ Bordeaux๐Ÿ“ Bordeaux Institut Curie ยท Tests: Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221Phase 31 site๐Ÿ“ Beijing Peking University ยท Tests: Goserelin+TAM+AI, Epirubicin+CTX+5-Fu A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites๐Ÿ“ Huntsville๐Ÿ“ Tucson๐Ÿ“ Duarte Genentech, Inc. ยท Tests: GDC-4198, Giredestrant, Abemaciclib Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor NCT05181033Phase 21 site๐Ÿ“ Singapore National University Hospital, Singapore ยท Tests: Lenvatinib + Letrozole, Fulvestrant A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site๐Ÿ“ Shanghai Forward Pharmaceuticals Co., Ltd. ยท Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer NCT05601440Phase 210 sites๐Ÿ“ Calgary๐Ÿ“ Kelowna๐Ÿ“ Vancouver Canadian Cancer Trials Group ยท Tests: RP-6306, Gemcitabine, Observation, Niraparib, Fulvestrant Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites๐Ÿ“ Chicago๐Ÿ“ Chicago๐Ÿ“ Chicago Northwestern University ยท Tests: elacestrant, palbociclib, abemaciclib, ribociclib Role of the Immune Environment in Response to Therapy in Breast Cancer NCT05396612n/a1 site๐Ÿ“ Philadelphia Abramson Cancer Center at Penn Medicine ยท Tests: Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA โ€ฆ OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328Phase 42 sites๐Ÿ“ Seoul๐Ÿ“ Seoul Gangnam Severance Hospital ยท Tests: Ovarian function suppression with endocrine treatments IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases NCT06092892Phase 23 sites๐Ÿ“ Los Angeles๐Ÿ“ Pasadena๐Ÿ“ Tarzana Alice Chung ยท Tests: Breast Surgery (BCS or mastectomy) with TAD/SNB, Adjuvant Radiation Therapy A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites๐Ÿ“ Lake Mary๐Ÿ“ Sarasota๐Ÿ“ Cincinnati Edgewood Oncology Inc. ยท Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ San Diego RayzeBio, Inc. ยท Tests: RYZ101, Standard of Care Endocrine Therapy Combined Immunotherapies in Metastatic ER+ Breast Cancer NCT04563507Phase 23 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer NCT06167694Phase 1, Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Shandong Suncadia Medicine Co., Ltd. ยท Tests: HRS-8080; Dalpiciclib Isethionate Tablets NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites๐Ÿ“ Sankt Gallen๐Ÿ“ Genolier๐Ÿ“ Winterthur Swiss Cancer Institute ยท Tests: Doxycyclin Breast Cancer Evolution During Neoadjuvant Systemic Therapy NCT06681064n/a1 site๐Ÿ“ London Royal Marsden NHS Foundation Trust Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774Phase 3226 sites๐Ÿ“ Jonesboro๐Ÿ“ Auburn๐Ÿ“ Berkeley National Cancer Institute (NCI) ยท Tests: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography Breast Re-irradiation After Second Ipsilateral Lumpectomy NCT06867484NA2 sites๐Ÿ“ Boca Raton๐Ÿ“ Miami Youssef Zeidan ยท Tests: Intensity modulated radiation therapy (IMRT) Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy NCT06953882Phase 21 site๐Ÿ“ New Haven Yale University ยท Tests: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 NCT05879926Phase 31261 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage NRG Oncology ยท Tests: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression Capecitabine in ER+/HER2-negative Breast Cancer NCT07631052Phase 21 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Capecitabine A Study of Neoadjuvant TCHpy๏ผˆPyrotinib ๏ผŒTrastuzumab๏ผŒCarboplatin and Paclitaxel๏ผ‰for ER+/HER2+ Breast Cancer NCT06000917Phase 22 sites๐Ÿ“ Wuhan๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: pyrotinib,Trastuzumab๏ผŒcarboplatin๏ผŒAlbumin paclitaxel Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients NCT07235176Phase 1, Phase 21 site๐Ÿ“ Shanghai Qilu Pharmaceutical Co., Ltd. ยท Tests: QLS1304 tablet+Fulvestrant or QLC1401, QLS1304 tablet+Fulvestrant๏ผŒAI or QLC1401+CDK4/6i
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy